Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osimertinib + quaratusugene ozeplasmid
- Development stage
- Unknown
- Lead developer
- Genprex
- Modality
- Small Molecules, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of osimertinib, an EGFR tyrosine kinase inhibitor, and quaratusugene ozeplasmid, a gene therapy that delivers the TUSC2 tumor suppressor gene via non-viral lipid nanoparticles. This combination is being investigated for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations that has progressed after osimertinib treatment. Quaratusugene ozeplasmid targets the TUSC2 gene and is designed to interrupt cell signaling pathways, recreate pathways for apoptosis in cancer cells, modulate immune response against cancer cells, and block the development of drug resistance.
- Brand names
- Tagrisso + Reqorsa
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUSC2 (Tumor suppressor candidate 2)
Beyond the preview
Go deeper on osimertinib + quaratusugene ozeplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osimertinib + quaratusugene ozeplasmid.